Clinical Trial: Detection Technology of Peripheral Blood ctDNA Based on CRISPR/Cas and Gold Nanoparticles

U.S., Nov. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07916636) titled 'Detection Technology of Peripheral Blood ctDNA Based on CRISPR/Cas and Gold Nanoparticles' on Oct. 23.

Brief Summary: This study tests a new, fast blood test that may help detect very small traces of tumor DNA in the bloodstream. When tumor cells die, they release small pieces of DNA called circulating tumor DNA (ctDNA) into the blood. Finding these pieces can help doctors diagnose cancer, monitor how well treatment is working, and detect cancer recurrence earlier. However, ctDNA is present in very small amounts and is hard to detect with current methods. Newer techniques such as next-generation sequencing (NGS) can find ctDNA, but t...